BMS 493 is primarily utilized in research settings as a retinoic acid receptor (RAR) pan-antagonist. It is widely employed in studies focusing on the role of retinoic acid signaling pathways in various biological processes, including embryonic development, cell differentiation, and tissue homeostasis. Researchers use this compound to inhibit RAR activity, allowing them to investigate the effects of disrupted retinoic acid signaling in cellular and animal models. Additionally, BMS 493 has been instrumental in exploring potential therapeutic strategies for diseases where retinoic acid pathways are dysregulated, such as certain cancers and skin disorders. Its application in experimental pharmacology helps in understanding the molecular mechanisms underlying these conditions and in developing targeted treatments.